Hims & Hers Health shares plunge 17.5% on profit and outlook cut
The telehealth provider cut its 2026 earnings forecast despite strong revenue growth, prompting a sharp sell-off that erased nearly a fifth of its value.
The telehealth provider cut its 2026 earnings forecast despite strong revenue growth, prompting a sharp sell-off that erased nearly a fifth of its value. Published 2026-11-10 by Falling Shares.
| By Falling Shares Intelligence, edited by Wung Thomas, Editor-in-Chief
Written by Falling Shares Intelligence, our automated newsroom, from the public sources listed below and live market data. Every figure is checked against that material before publication, but the story has not been reviewed by a human editor. Check the linked sources before relying on it, and report errors to info@fallingshares.com.
Shares in Hims & Hers Health fell 17.54% on Tuesday after the company cut its full-year profit outlook and warned of subscriber uncertainty, a drop that pushed the stock to seven-month lows. The sell-off came after the telehealth provider reported third-quarter results that disappointed investors and signaled margin pressure.
Guidance cut sparks sell-off
Hims & Hers Health reported a significant decline in profitability for the third quarter, leading the company to lower its 2026 earnings forecast. According to Yahoo Finance, the stock sank after these results and the disappointing outlook were released. Proactive reported that the company trimmed its revenue forecast for 2026 even as it posted 49% revenue growth, a combination that failed to reassure the market.
The company’s guidance cut was a primary driver of the sharp decline. GuruFocus.com noted that the stock plunged as profit vanished and its growth engine sputtered. TradersUnion highlighted that the fall was pressured by weak earnings, margin contraction, and lower forward guidance, with the stock trading at $22.94 after an 11.75% drop in earlier sessions.
Subscriber trends weigh on value
Jefferies warned that Hims & Hers may see heightened price gyrations as trends in weight-loss drugs fuel subscriber uncertainty. Stocktwits reported this warning alongside the news that the stock hit seven-month lows. The broker’s caution showed the challenges facing the company’s core business model as consumer preferences shift.
The company’s chief executive acknowledged the difficulty of the environment, telling Reuters that he would take subscriber losses "every time" if it meant protecting margins. This stance was reported by TIKR, which noted the stock had already sunk 9% on the EBITDA guidance cut prior to the final session's larger decline.